Knight Therapeutics Inc. reconfirmed earnings guidance for the year 2024. Knight expects to generate between $335 million to $350 million in revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.01 CAD | +1.35% | +0.17% | +15.80% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.80% | 445M | |
+16.93% | 79.23B | |
+8.92% | 8.66B | |
-17.73% | 4.72B | |
+56.03% | 4.89B | |
+1.31% | 3.81B | |
+18.99% | 2.42B | |
-25.43% | 2.22B | |
+14.61% | 2.08B | |
-37.31% | 1.96B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024